Trial Profile
A real world, retrospective study to evaluate use of Secukinumab by describing demographic, clinical and treatment characteristics in patients with Psoriatic arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2017
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 02 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism